CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Chief Executive Officer, John Climaco, on Wednesday, June 17th at 4:00 PM ET
6月17日下午4点ET与首席执行官约翰·克莱马科进行现场视频网络直播
HOUSTON, TX / ACCESSWIRE / July 16, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in the Virtual Investor Closing Bell Series on Wednesday, June 17, 2024 at 4:00 PM ET.
TX休斯顿/ACCESSWIRE/2024年7月16日/CNS药品公司（NASDAQ：CNSP）（“CNS”或“公司”），一家专门从事开发治疗脑部和中枢神经系统原发性和转移性癌症的创新药物的生物制药公司，今天宣布，CNS药物公司的首席执行官约翰·克莱马科将于2024年6月17日下午4点ET参加虚拟投资者收盘钟系列活动。
As part of the event, Mr. Climaco will provide a corporate overview. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Climaco will answer as many questions as possible in the time allowed.
作为此次活动的一部分，克莱马科先生将提供公司概述， 除准备好的讲话外，感兴趣的各方将有机会在活动期间实时提交问题，克莱马科先生将尽可能在允许的时间内回答尽可能多的问题。
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
演示的现场视频网络直播将在公司网站（cnspharma.com）的投资者页面上提供。现场演示结束后两小时，将提供网络直播重播，并可访问90天。
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
关于CNS制药公司
CNS药品有限公司是一家处于临床阶段的药品公司，正在开发一系列治疗脑部和中枢神经系统原发性和转移性癌症的候选药物。公司的领先药物候选Berubicin是一种新型蒽环类似物，也是第一种似乎可以穿过血脑屏障的蒽环类似物。Berubicin当前正在开发用于治疗许多严重的脑和中枢神经系统肿瘤指标，包括恶性胶质瘤（GBM），这是一种侵袭性和不可治愈的脑癌。
For more information, please visit , and connect with the Company on X, Facebook, and LinkedIn.
欲了解更多信息，请访问X，并通过Facebook和LinkedIn与公司联系。
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-4717-8247
CNSP@jtcir.com
联系方式：
投资者关系联系人
JTC Team，LLC
Jenene Thomas
833-4717-8247
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
信息来源：CNS制药公司。